Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 10/20 | 0.33 |
| ▸ | HTR2C | P28335 | 3/20 | 0.33 |
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | HTR2B | P41595 | 2/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10241538 | 0.90 | PTGS2 (0.37) | LMNASLC6A4PTGS2SLC6A2HTR2C | |
| SCHEMBL10188806 | 0.72 | PTGS2 (0.35) | SLC6A4PTGS2OPRK1SLC6A2HTR2C | |
| SCHEMBL13720499 | 0.71 | TSHR (0.40) | LMNACYP2D6HTT | |
| SCHEMBL4022057 | 0.71 | TSHR (0.40) | LMNACYP2D6HTT | |
| SCHEMBL13045928 | 0.70 | KCNH2 (0.39) | MAOB | |
| SCHEMBL9951558 | 0.69 | HTR2A (0.35) | PTGS2OPRK1HTR2CHTR2AHTR2B | |
| SCHEMBL9951554 | 0.69 | HTR2A (0.35) | PTGS2OPRK1HTR2CHTR2AHTR2B | |
| SCHEMBL16638921 | 0.67 | SLC6A2 (0.31) | SLC6A2 | |
| SCHEMBL27544386 | 0.66 | MAOB (0.34) | LMNAMAOBHTTSMN1; SMN2 | |
| SCHEMBL4689210 | 0.66 | MAOB (0.33) | HTR2CHTR2AHTR2BMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268848-B2 | Cyclopropane compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-09-18 | — | — | US | disclosed |
| US-20120095031-A1 | CYCLOPROPANE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095031-A1 | CYCLOPROPANE COMPOUND | HCRTR1, HCRTR2, CNR1 | LMNA 3446/4885SLC6A4 370/4885PTGS2 2258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.